| Literature DB >> 29105735 |
Teri A Manolio1, Carolyn M Hutter1, Mark Avigan2, Ricardo Cibotti3, Robert L Davis4, Joshua C Denny5, Lois La Grenade2, Lisa M Wheatley6, Mary N Carrington7, Wasun Chantratita8, Wen-Hung Chung9, Andrea D Dalton10, Shuen-Iu Hung11, Ming Ta Michael Lee12, J Steven Leeder13, Juan J L Lertora14, Surakameth Mahasirimongkol15, Howard L McLeod16, Maja Mockenhaupt17, Michael Pacanowski2, Elizabeth J Phillips18,19, Simone Pinheiro2, Munir Pirmohamed20, Cynthia Sung21, Wimon Suwankesawong22, Lauren Trepanier23, Santa J Tumminia24, David Veenstra25, Rika Yuliwulandari26, Neil H Shear27.
Abstract
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is one of the most devastating of adverse drug reactions (ADRs) and was, until recently, essentially unpredictable. With the discovery of several risk alleles for drug-induced SJS/TEN and the demonstration of effectiveness of screening in reducing incidence, the stage is set for implementation of preventive strategies in populations at risk. Yet much remains to be learned about this potentially fatal complication of commonly used drugs.Entities:
Mesh：
Year: 2017 PMID： 29105735 PMCID： PMC5805563 DOI： 10.1002/cpt.890
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875